MassVentures — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection.
BiotechDeep TechHardwareCambridge, US
Cullen Buie(Director)inPaulo Garcia(Executive Officer, Director, Promoter)inMichael Chiu(Director, Executive Officer)in
BoardPaxton Major(Director)inAnn DeWitt(Director)inPaul Wotton(Director)
Co-investorsBantam GroupHorizons VenturesSelvedge VentureTBD AngelsTelegraph Hill PartnersThe Engine Ventures+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.